Sigyn Therapeutics (SIGY) Cash from Operations (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Cash from Operations of 199326.0 for Q3 2025, down 30.76% sequentially from 152436.0 in Q2 2025, and down 21.68% YoY from 254501.17 in Q3 2024.
Sigyn Therapeutics (SIGY) Cash from Operations (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Cash from Operations for 10 years, with the latest figure at 199326.0 in Q3 2025.
- Quarterly Cash from Operations fell 21.68% year-over-year to 199326.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 936426.0 (down 31.87% YoY) and the FY2024 annual result came in at 872436.0, up 36.93% from the prior year.
- Cash from Operations declined to 199326.0 in Q3 2025 per SIGY's latest filing, from 152436.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 127894.0 in Q4 2023 and troughed at 562573.0 in Q1 2023.
- A 5-year average of 342435.68 and a median of 328694.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2021 and 2023: Cash from Operations plunged 201.93% in 2021, then soared 71.69% in 2023.
- Over 5 years, Cash from Operations stood at 552961.0 in 2021, then gained by 18.3% to 451767.0 in 2022, then jumped by 71.69% to 127894.0 in 2023, then tumbled by 126.92% to 290218.0 in 2024, then soared by 31.32% to 199326.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 199326.0, 152436.0, and 294446.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -199,326.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -199,326.00 |
| Sep 30, 2025 | -199,326.00 |
| Jun 30, 2025 | -152,436.00 |
| Jun 30, 2025 | -152,436.00 |
| Mar 31, 2025 | -294,446.00 |
| Mar 31, 2025 | -294,446.00 |
| Dec 31, 2024 | -290,218.00 |
| Dec 31, 2024 | -290,218.00 |
| Sep 30, 2024 | -163,812.00 |
| Sep 30, 2024 | -163,812.00 |
| Jun 30, 2024 | -182,794.00 |
| Jun 30, 2024 | -182,794.00 |
| Mar 31, 2024 | -235,612.00 |
| Mar 31, 2024 | -235,612.00 |
| Dec 31, 2023 | -127,894.00 |
| Dec 31, 2023 | -127,894.00 |
| Sep 30, 2023 | -364,049.00 |
| Sep 30, 2023 | -364,049.00 |
| Jun 30, 2023 | -328,694.00 |
| Jun 30, 2023 | -328,694.00 |